Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature Reviews Drug Discovery (42)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Comments & Opinion (39)
Amendments and Corrections (2)
News (1)

Subject Check one or more subjects to show results from those subjects only.

Diseases
Drug discovery
Genetics
Health care
Signs and symptoms

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–42 of 42 results

Advanced filters: Author: Uma Yasothan Clear advanced filters

Romiplostim

Douglas B. Cines
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 Nov 2008
Nature Reviews Drug Discovery

Volume: 7, P: 887-888
Ruxolitinib

Janus kinase inhibitor approved by the US Food and Drug Administration for the treatment of myelofibrosis.

Ruben A. Mesa
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 Feb 2012
Nature Reviews Drug Discovery

Volume: 11, P: 103-104
Ivacaftor

First disease-modifying drug approved in the United States for the treatment of cystic fibrosis in patients with a specific mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator.

Pamela B. Davis
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion30 Apr 2012
Nature Reviews Drug Discovery

Volume: 11, P: 349-350
Belimumab

Iñaki Sanz
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion29 Apr 2011
Nature Reviews Drug Discovery

Volume: 10, P: 335-336
Alvimopan

Conor P. Delaney
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 Sept 2008
Nature Reviews Drug Discovery

Volume: 7, P: 727-728
Vemurafenib

Keith. T Flaherty
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion31 Oct 2011
Nature Reviews Drug Discovery

Volume: 10, P: 811-812
Everolimus

Michael B. Atkins
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 Jul 2009
Nature Reviews Drug Discovery

Volume: 8, P: 535-536
Telavancin

G. Ralph Corey
Martin E. Stryjewski
Peter Kirkpatrick
Comments & Opinion01 Dec 2009
Nature Reviews Drug Discovery

Volume: 8, P: 929-930
Tetrabenazine

Michael R. Hayden
Blair R. Leavitt
Peter Kirkpatrick
Comments & Opinion01 Jan 2009
Nature Reviews Drug Discovery

Volume: 8, P: 17-18
Tocilizumab

Clemens Scheinecker
Josef Smolen
Peter Kirkpatrick
Comments & Opinion01 Apr 2009
Nature Reviews Drug Discovery

Volume: 8, P: 273-274
Velaglucerase alfa

Johannes M. F. G. Aerts
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion29 Oct 2010
Nature Reviews Drug Discovery

Volume: 9, P: 837-838
Brentuximab vedotin

Antibody–drug conjugate specific for CD30 approved by the US Food and Drug Administration for the treatment of two types of lymphoma.

Anas Younes
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion03 Jan 2012
Nature Reviews Drug Discovery

Volume: 11, P: 19-20
Crizotinib

Alice T. Shaw
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 Dec 2011
Nature Reviews Drug Discovery

Volume: 10, P: 897-898
Pirfenidone

Luca Richeldi
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 Jul 2011
Nature Reviews Drug Discovery

Volume: 10, P: 489-490
Denosumab

René Rizzoli
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 Aug 2010
Nature Reviews Drug Discovery

Volume: 9, P: 591-592
Icatibant

Konrad Bork
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 Oct 2008
Nature Reviews Drug Discovery

Volume: 7, P: 801-802
Dabigatran etexilate

Bengt I. Eriksson
Helen Smith
Peter Kirkpatrick
Comments & Opinion01 Jul 2008
Nature Reviews Drug Discovery

Volume: 7, P: 557-558
Tolvaptan

Jalal K. Ghali
Bashar Hamad
Peter Kirkpatrick
Comments & Opinion01 Aug 2009
Nature Reviews Drug Discovery

Volume: 8, P: 611-612
Pazopanib

Ronald M. Bukowski
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 Jan 2010
Nature Reviews Drug Discovery

Volume: 9, P: 17-18
Pasireotide

Somatostatin analogue approved as the first pharmacotherapy for Cushing's disease in the European Union.

Richard A. Feelders
Uma Yasothan
Peter Kirkpatrick
News01 Aug 2012
Nature Reviews Drug Discovery

Volume: 11, P: 597-598
Bendamustine

Michael J. Keating
Christian Bach
Peter Kirkpatrick
Comments & Opinion01 Jun 2008
Nature Reviews Drug Discovery

Volume: 7, P: 473-474
Etravirine

Richard Haubrich
Steven Gubernick
Peter Kirkpatrick
Comments & Opinion01 Apr 2008
Nature Reviews Drug Discovery

Volume: 7, P: 287-288
Plerixafor

John F. DiPersio
Geoffrey L. Uy
Peter Kirkpatrick
Comments & Opinion01 Feb 2009
Nature Reviews Drug Discovery

Volume: 8, P: 105-107
Ecallantide

Bruce Zuraw
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 Mar 2010
Nature Reviews Drug Discovery

Volume: 9, P: 189-190
Prasugrel

Kurt Huber
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 Jun 2009
Nature Reviews Drug Discovery

Volume: 8, P: 449-450
Febuxostat

Eliseo Pascual
Francisca Sivera
Peter Kirkpatrick
Comments & Opinion01 Mar 2009
Nature Reviews Drug Discovery

Volume: 8, P: 191-192
Roflumilast

Leonardo M. Fabbri
Bianca Beghé
Peter Kirkpatrick
Comments & Opinion01 Oct 2010
Nature Reviews Drug Discovery

Volume: 9, P: 761-762
Ofatumumab

Michael J. Keating
Argyris Dritselis
Peter Kirkpatrick
Comments & Opinion01 Feb 2010
Nature Reviews Drug Discovery

Volume: 9, P: 101-102
Rilonacept

Hal M. Hoffman
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 May 2008
Nature Reviews Drug Discovery

Volume: 7, P: 385-386
Certolizumab pegol

Gil Y. Melmed
Stephan R. Targan
Peter Kirkpatrick
Comments & Opinion01 Aug 2008
Nature Reviews Drug Discovery

Volume: 7, P: 641-642
Asenapine

Herbert Y. Meltzer
Argyris Dritselis
Peter Kirkpatrick
Comments & Opinion01 Nov 2009
Nature Reviews Drug Discovery

Volume: 8, P: 843-844
Pegloticase

Naomi Schlesinger
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion31 Dec 2010
Nature Reviews Drug Discovery

Volume: 10, P: 17-18
Lacosamide

Emilio Perucca
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 Dec 2008
Nature Reviews Drug Discovery

Volume: 7, P: 973-974
Golimumab

Dimitrios A. Pappas
Joan M. Bathon
Peter Kirkpatrick
Comments & Opinion01 Sept 2009
Nature Reviews Drug Discovery

Volume: 8, P: 695-696
Sipuleucel-T

Celestia S. Higano
Eric J. Small
Philip W. Kantoff
Comments & Opinion01 Jul 2010
Nature Reviews Drug Discovery

Volume: 9, P: 513-514
Ustekinumab

Kristian Reich
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 May 2009
Nature Reviews Drug Discovery

Volume: 8, P: 355-356
Publisher Correction: Roflumilast

Leonardo M. Fabbri
Bianca Beghé
Peter Kirkpatrick
Amendments and Corrections15 May 2024
Nature Reviews Drug Discovery

Volume: 23, P: 563
Erratum: Pegloticase

Naomi Schlesinger
Uma Yasothan
Peter Kirkpatrick
Amendments and Corrections01 Feb 2011
Nature Reviews Drug Discovery

Volume: 10, P: 156
Osteoporosis: overview and pipeline

Uma Yasothan
Santwana Kar
Comments & Opinion01 Sept 2008
Nature Reviews Drug Discovery

Volume: 7, P: 725-726
Therapies for COPD

Uma Yasothan
Santwana Kar
Comments & Opinion01 Apr 2008
Nature Reviews Drug Discovery

Volume: 7, P: 285-286
Inhaled aztreonam

Brian P. O'Sullivan
Uma Yasothan
Peter Kirkpatrick
Comments & Opinion01 May 2010
Nature Reviews Drug Discovery

Volume: 9, P: 357-358
Rheumatoid arthritis market

Jeffrey G. Stoll
Uma Yasothan
Comments & Opinion01 Sept 2009
Nature Reviews Drug Discovery

Volume: 8, P: 693-694